
About ICLUSIG® (ponatinib)
Who is ICLUSIG for?
ICLUSIG is a prescription medicine used to treat adults who have:
- Chronic phase chronic myeloid leukemia (CML) who did not tolerate or no longer benefit from treatment with at least 2 prior kinase inhibitor medicines
- Accelerated phase or blast phase CML, or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who cannot receive any other kinase inhibitor medicines
- A specific type of abnormal gene (T315I-positive) chronic phase, accelerated phase, or blast phase CML, or T315I-positive Ph+ ALL
ICLUSIG is not for use to treat people with newly diagnosed chronic phase CML.
It is not known if ICLUSIG is safe and effective in children.
ICLUSIG dosing
ICLUSIG is taken once daily, at the same time
ONE TABLET
ONCE A DAY
WITH OR WITHOUT FOOD
Starting dose in CML
The recommended starting dose of ICLUSIG is 45 mg once a day. For people with chronic phase or accelerated phase CML, your doctor may reduce the dose if ICLUSIG is working for you. Your doctor may stop ICLUSIG if you experience side effects or do not respond to treatment.
Starting dose in Ph+ ALL
The recommended starting dose of ICLUSIG is 45 mg once a day. Your doctor may stop ICLUSIG if you experience side effects or do not respond to treatment.
How should I take ICLUSIG?
- Take ICLUSIG exactly as your doctor tells you to take it
- Do not change your dose or stop taking ICLUSIG unless your doctor tells you
- Swallow ICLUSIG tablets whole. Do not crush, break, cut, chew, or dissolve ICLUSIG tablets
- Take ICLUSIG with or without food
- Do not eat grapefruit or drink grapefruit juice during treatment with ICLUSIG
- If you miss a dose of ICLUSIG, take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose
- If you take too much ICLUSIG, call your doctor or go to the nearest hospital emergency room right away
How does ICLUSIG work?
ICLUSIG helps to stop cancer causing BCR-ABL proteins from creating cancerous cells. ICLUSIG has been shown to work even if these proteins have developed a type of mutation called the T315I mutation.
Working closely with your healthcare team can help you remain confident as you continue your treatment journey.
Talking to your doctor about ICLUSIG
It’s normal to have questions about your treatment. That’s why it’s important to work closely with your healthcare team and understand your treatment plan.
Talk to your doctor about the information you’ve read here.
And be sure to ask questions like:
- Is ICLUSIG the appropriate next step for me?
- How can ICLUSIG help?
- What is the recommended dose of ICLUSIG?
- What are the side effects of ICLUSIG?
Side effects with ICLUSIG
Get details about potential side effects from clinical studies.